|
rs12435998
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The SNP rs12435998 was prevalent in anaplastic and malignant gliomas, and in meningiomas of all histologic grades, but unrelated to brain tumor risks.
|
25948789 |
2015 |
|
rs2298881
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In a stratification analysis, we found that ERCC1 rs22</span>98881 variants showed an increased association with the risk of glioma in males, ever smokers, and high-grade glioma cases.
|
24782032 |
2014 |
|
rs11554137
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The SNP rs11554137 is independent of the occurrence of somatic mutation on IDH1 codon 132, but, per se, has a prognostic impact in malignant gliomas.
|
23184331 |
2013 |
|
rs55819519
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Of 158 tumors with sufficient tissue, 110 (70 %) showed nuclear cMYC immunopositivity--most frequent (95 %, χ(2) p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 %) or low grade gliomas (74 %). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort.
|
23934175 |
2013 |
|
rs1805015
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The IL4R rs1805016 and rs1805015 TT genotypes were both found to be significantly associated with survival beyond 1 year among patients with high-grade glioma (HR, 0.44; 95% CI, 0.27-0.73 and HR, 0.63; 95% CI, 0.44-0.91, respectively).
|
18927306 |
2008 |
|
rs1805016
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The IL4R rs1805016 and rs1805015 TT genotypes were both found to be significantly associated with survival beyond 1 year among patients with high-grade glioma (HR, 0.44; 95% CI, 0.27-0.73 and HR, 0.63; 95% CI, 0.44-0.91, respectively).
|
18927306 |
2008 |